Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic lymphocytic leukemia
Pharma
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
The addition of Jaypirca to a fixed-duration regimen with venetoclax and rituximab improved PFS by 45.3% in previously treated CLL.
Angus Liu
Jun 15, 2026 8:25am
Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial
Apr 13, 2026 10:16am
AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push
Feb 20, 2026 11:05am
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Dec 9, 2025 7:30am
Lilly's BTK inhibitor Jaypirca wins lymphoma label expansion
Dec 3, 2025 8:25am
AbbVie film showcases 'Second Winds' of life after CLL diagnosis
Nov 25, 2025 12:41pm
